Authors: A. Wollenberg; C. Flohr; D. Simon; M.J. Cork; J.P. Thyssen; T. Bieber; M.S. de Bruin‐Weller; S. Weidinger; M. Deleuran; A. Taieb; C. Paul; M. Trzeciak; T. Werfel; J. Seneschal; S. Barbarot; U. Darsow; A. Torrelo; J.‐F. Stalder; Å. Svensson; D. Hijnen; C. Gelmetti; Z. Szalai; U. Gieler; L. De Raeve; B. Kunz; P. Spuls; L.B. von Kobyletzki; R. Fölster‐Holst; P.V. Chernyshov; S. Christen‐Zaech; A. Heratizadeh; J. Ring; C. Vestergaard

Venue: Journal of the European Academy of Dermatology and Venereology

Type: Publication

Abstract: Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities. Severely affected patients are often treated with immune‐modulating systemic drugs. On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS‐Cov‐2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno‐compromised, or have comorbidities. This also applies to AD patients ... (read more)

DOI: 10.48350/149467